Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

(NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults earlier this month. “This is a major step forward ...

Sleep expert Dr. Abhay Sharma talks about how Zepbound is now approved by the FDA for the treatment of moderate to severe ...

In December, the FDA approved Zepbound as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. It should be used with a reduced ...

(NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults earlier this month. “This is a major step forward for ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.